v3.26.3
Goodwill and Other Purchased Intangible Assets
 9 Months Ended
Sep. 30, 2026
Intangible Asset, Goodwill and Other [Abstract]  
Goodwill and Other Purchased Intangible Assets
4. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):
Life
Science
Clinical
Diagnostics
Total
Balances as of December 31, 2025
Goodwill$493.2 $421.8 $915.0 
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net451.4 128.4 579.8 
Acquisition adjustments(1.1)— (1.1)
Foreign currency adjustments(5.7)— (5.7)
Period change, net
(6.8)— (6.8)
Balances as of September 30, 2026
Goodwill486.4 421.8 908.2 
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net$444.6 $128.4 $573.0 
Information regarding our identifiable purchased intangible assets with finite lives is as follows (in millions):
September 30, 2026
Weighted-Average Amortization Period (in years)
Purchase
Price		Accumulated
Amortization		Net Carrying
Value
Customer relationships/lists3.7$109.1 $(102.7)$6.4 
Developed product technology9.1235.9 (145.8)90.1 
Licenses2.459.4 (52.2)7.2 
Tradenames2.86.0 (5.3)0.7 
     Total purchased intangible assets$410.4 $(306.0)$104.4 
December 31, 2025
Weighted-Average Amortization Period (in years)
Purchase
Price		Accumulated
Amortization		Net Carrying
Value
Customer relationships/lists4.4$115.6 $(107.7)$7.9 
Developed product technology10.7315.8 (160.0)155.8 
Licenses3.159.8 (50.3)9.5 
Tradenames3.66.0 (5.1)0.9 
Covenants not to compete0.56.5 (6.3)0.2 
     Total purchased intangible assets$503.7 $(329.4)$174.3 

Amortization expense related to purchased intangible assets was as follows (in millions):

Three Months EndedNine Months Ended
September 30,September 30,
2026202520262025
Amortization expense$5.0 $7.3 $16.9 $17.5 

In 2020, the Company acquired Celsee, Inc. (“Celsee”), which developed and manufactured instruments and consumables for the isolation, detection, and analysis of single cells. During the third quarter of 2026, the Company decided to reduce research and development and marketing investment in single-cell products acquired in the Celsee acquisition, including closing the related facility under the restructuring plan. As a result, the Company determined that the carrying value of the acquired developed technology was not recoverable and recorded an impairment charge of $49.8 million, reducing its carrying value to zero. Fair value used in the impairment measurement was determined using an income approach based on Level 3 inputs. The expense is included in Impairment of purchased intangibles in the condensed consolidated statements of income (loss) for the three and nine months ended September 30, 2026, within the Life Science segment.